Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
Today, we are pleased to welcome a guest post from RADM Richardae Araojo, Pharm.D., MS, the Associate Commissioner for Minority Health Director, Office of Minority Health and Health Equity, U.S. Food and Drug Administration.
The FDA’s Office of Minority Health and Health Equity (OMHHE) was established in 2010 with the mission of protecting and promoting the health of racial and ethnic minority and other diverse populations through research, outreach, and communication of science that addresses health disparities. The office’s dedicated staff in the Research and Collaboration and Outreach and Communication programs work with a wide variety of public and private stakeholders to address the needs and concerns of diverse communities through developing tailored educational, outreach, training, and scientific initiatives that advance health equity.
One of our most notable and long-term initiatives over the last decade is the Diversity in Clinical Trials Initiative, a key priority area for OMHHE. In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. This piece of legislation, specifically section 907, emphasized the need for increased racial and ethnic minority participation in clinical trials. In response to FDASIA, OMHHE created the Diversity in Clinical Trials Initiative which includes an ongoing, multi-media, culturally and linguistically tailored, public education and outreach campaign to raise awareness on the need for racial and ethnic minority participation in clinical trials.
Historically, racial and ethnic minority populations have been underrepresented in clinical trials and the trend persists today. These same communities are often disproportionately burdened by many chronic and debilitating diseases like heart disease and diabetes, making the need for their participation in clinical research even more critical. There are many factors that can be attributed to lower participation rates among racial and ethnic communities in clinical research such as lack of trust in the medical system—in part due to past historical mistreatment—as well as a lack of transportation, time, language barriers, and knowledge or awareness of clinical research opportunities, to name a few.
Addressing barriers to diversifying clinical trials is critical to closing the health equity gap. The OMHHE Diversity in Clinical Trials Initiative includes a public education campaign with new resources added on a continual basis. The underlying premise of the campaign is to add positive messaging reflecting diverse spokespersons who are representative of diverse communities, while tailoring resources to be culturally and linguistically appropriate and translated into multiple languages (e.g. Spanish, Tagalog, Chinese, Vietnamese, among others). The campaign aims to combat myths and educate consumers about key issues while also helping to stimulate dialogue among peers and peer to provider groups.
The multi-faceted campaign includes public service announcements, patient videos, listening sessions, stakeholder engagement, public meetings, webinars, a dedicated website, podcast, print and digital health education, and social media outreach. Materials are easy to read and understand, feature culturally relevant images, and are translated into multiple languages. Videos within the campaign include specific disease and topic areas such as diversity in sickle cell disease clinical trials, Veterans and clinical trials, and the need for diversity in medical device clinical trials. Many videos also feature diverse spokespersons sharing their personal stories about clinical trial participation.
Another key component to the Initiative is stakeholder engagement. We realize that we cannot do this work in a silo and actively find opportunities to engage with stakeholders—including federal partners, industry, non-profit organizations, academia, community organizations, consumer groups, medical providers, among others to encourage diversity and inclusion in clinical trials. For example, we established a memorandum of understanding (MOU) with The Alliance for Multicultural Physicians and with Yale University. With The Alliance, we aim to collaborate on developing educational, outreach, and training initiatives for physicians and the diverse patients they serve to advance health equity. Our MOU with Yale focuses on advancing the Yale Cultural Ambassadors Program, an engagement of community partners to increase participation of diverse and historically underrepresented populations in clinical research. We have worked with many medical professional associations, non-profits, academia, among a range of other stakeholders to amplify the campaign’s reach. FDA also engages with industry collectively as industry is organizing efforts on clinical trial diversity.
Our office continues to work with patients to increase understanding and awareness within diverse communities of the benefits and risks of clinical research and to provide current and accurate information to help make informed decisions.
Achieving health equity requires commitment and dedication from stakeholders from all corners of the public health and research community. We can continue to make a difference when we work together towards this goal.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Mass compounding puts patients at risk
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
Major drug compounder is spending millions on misleading Super Bowl ad
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
Analysis: States can help patients save nearly $1,000 annually on their medicines
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
The importance of timely PDUFA and BsUFA reauthorization
Medicaid 101: Three charts on access and spending
Government price setting won’t stop insurers from shifting costs to patients
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Patients need to pay less for their medicines. States can help.
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
New study finds more than half of brand medicine spending goes to the supply chain and others
Making medicines more affordable: Preserving safety-net programs like 340B
Post-approval research save lives. Why is Congress trying disincentivize it?
A price control by any other name would still put patients at risk and threaten innovation
Making medicines more affordable: Making insurance work like insurance
3 things to know about the importance of post-approval research and development
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
What is missing in the current drug pricing plan
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
Making medicines more affordable: Sharing savings at the pharmacy counter
Three things to know about so-called Medicare negotiation polling
In the current health care debate, Congress has lost sight of what matters to U.S. voters
Making medicines more affordable: Modernizing Medicare
Making Medicines More Affordable: Making coupons count
What they are saying: Government price setting for medicines is not the answer
The patient experience: Insurance design hurdles lead to access issues for too many Americans
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
Government “negotiation” could have devastating consequences for Medicare enrollees
Protecting Medicare from government interference
3 factors impacting medication adherence for patients with diabetes
Data shows voters strongly support protecting access to their medicines
Medicare “negotiation” proposals threaten Americans’ access to medicines
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
How strengthening the biosimilar marketplace benefits patients
Four solutions Americans support to make health care more affordable
H.R. 3 threatens access to medicines, future innovation and American jobs
Our three-part approach to build a better health care system
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Guest Post: The importance of a modern FDA in drug discovery
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
FDA
Proactive Agenda
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research